Cargando…
Clinical neuropathology practice guide 06-2012: MGMT testing in elderly glioblastoma patients – yes, but how?
Abstract. In 2005, a seminal paper showed that glioblastoma patients aged 18 to 70, whose tumors have a methylated MGMT promoter have a better prognosis than patients with tumors carrying an unmethylated MGMT promoter. As a consequence of this and several confirmatory studies, routine MGMT testing i...
Autores principales: | Berghoff, Anna S., Preusser, Matthias |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dustri-Verlag Dr. Karl Feistle
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3663470/ https://www.ncbi.nlm.nih.gov/pubmed/23083460 http://dx.doi.org/10.5414/NP300576 |
Ejemplares similares
-
Clinical Neuropathology practice guide 5-2015: MGMT methylation pyrosequencing in glioblastoma: unresolved issues and open questions
por: Bienkowski, Michal, et al.
Publicado: (2015) -
Clinical neuropathology practice news 2-2012: BRAF V600E testing
por: Capper, David, et al.
Publicado: (2012) -
Clinical Neuropathology practice news 1-2014: Pyrosequencing meets clinical and analytical performance criteria for routine testing of MGMT promoter methylation status in glioblastoma
por: Preusser, Matthias, et al.
Publicado: (2014) -
Clinical Neuropathology Practice News 4-2012: levels of evidence for brain tumor biomarkers
por: Berghoff, Anna Sophie, et al.
Publicado: (2012) -
Clinical Neuropathology mini-review 6-2015: PD-L1: emerging biomarker in glioblastoma?
por: Preusser, Matthias, et al.
Publicado: (2015)